{
  "image_filename": "table_p5_det_4_014.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p5_det_4_014.png",
  "image_type": "Table",
  "page_number": 5,
  "block_id": "det_4_014",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A table titled \u201cEfficacy of Cell-based Quadrivalent Vaccine vs Egg-based Quadrivalent Vaccine in HD-IIV4 Efficacy Trial: 2021\u20132022 (Per-Protocol Efficacy Population)\u201d, listing endpoints (laboratory-confirmed influenza due to any strain, vaccine match strain, and vaccine mismatch strain), number of events in each group (QIVc vs QIVe), relative vaccine efficacy percentages with 95% confidence intervals, and serotype breakdowns for match and mismatch strains. does not support the claim: the table presents efficacy data comparing cell-based and egg-based vaccines, not data on recombinant technology or its cross-protective immune response. Note: The table focuses on cell-based versus egg-based vaccine efficacy; recombinant technology is not addressed and no text explicitly mentions broader immune response or cross-protection from recombinant vaccine.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table titled \u201cEfficacy of Cell-based Quadrivalent Vaccine vs Egg-based Quadrivalent Vaccine in HD-IIV4 Efficacy Trial: 2021\u20132022 (Per-Protocol Efficacy Population)\u201d, listing endpoints (laboratory-confirmed influenza due to any strain, vaccine match strain, and vaccine mismatch strain), number of events in each group (QIVc vs QIVe), relative vaccine efficacy percentages with 95% confidence intervals, and serotype breakdowns for match and mismatch strains.",
    "evidence_found": null,
    "reasoning": "does not support the claim: the table presents efficacy data comparing cell-based and egg-based vaccines, not data on recombinant technology or its cross-protective immune response.",
    "confidence_notes": "The table focuses on cell-based versus egg-based vaccine efficacy; recombinant technology is not addressed and no text explicitly mentions broader immune response or cross-protection from recombinant vaccine."
  }
}